Argenx SE stock (NL0010832176): focus on Vyvgart growth after latest earnings update

Argenx SE remains in focus after its latest quarterly results and updates around Vyvgart and pipeline progress. US investors are watching the rare-disease specialist’s revenue trajectory and cash position amid a competitive autoimmune landscape.

Argenx SE, the Dutch-Belgian biotechnology group focused on autoimmune diseases, stayed in the spotlight after reporting its latest quarterly results and providing updates on the rollout of Vyvgart, its lead therapy for generalized myasthenia gravis and other IgG?mediated conditions. The company’s most recent earnings release highlighted ongoing revenue growth, a strong cash position and continued investment in its clinical pipeline, according to information published by the company and major financial news services in early 2025 and early 2026, including an earnings update on February 27, 2025 and subsequent quarterly disclosures referenced by outlets such as Reuters and company investor materials.

As of: 19.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Argenx SE
• Sector/industry: Biotechnology, autoimmune therapies
• Headquarters/country: The Netherlands / Belgium
• Core markets: United States, Europe, Japan and other international markets
• Key revenue drivers: Vyvgart franchise for generalized myasthenia gravis and other IgG?mediated diseases
• Home exchange/listing venue: Nasdaq (ticker: ARGX); Euronext Brussels
• Trading currency: USD on Nasdaq; EUR on Euronext Brussels

Argenx SE: core business model

Argenx SE is a clinical?stage and commercial?stage biotechnology company developing antibody?based therapies for severe autoimmune diseases and certain cancers. The group is best known for Vyvgart, a therapy that targets the neonatal Fc receptor (FcRn) to reduce pathogenic IgG antibodies. This mechanism is designed to treat conditions where autoantibodies drive disease activity, such as generalized myasthenia gravis.

The company’s business model combines in?house research with selective partnerships. Its proprietary SIMPLE Antibody platform is used to generate and optimize antibody candidates, while collaborations with larger pharmaceutical groups can support development and commercialization outside key focus regions. Over recent quarters, Argenx SE has emphasized its ambition to build a diversified autoimmune portfolio around the FcRn pathway, in addition to earlier?stage assets targeting other immune mechanisms.

Commercially, Argenx SE is transitioning from a pure R&D story to a more balanced profile with a growing revenue base. Vyvgart and related formulations represent the main source of product sales, while milestone and collaboration payments from partners provide additional but less predictable income. The company still invests heavily in research and development, which weighs on profitability, a pattern typical for mid?cap biotech groups that are in the scaling phase of a first major product launch.

Main revenue and product drivers for Argenx SE

Revenue growth at Argenx SE is currently driven by the Vyvgart franchise. The initial intravenous formulation was first approved for generalized myasthenia gravis and has since seen broader geographic rollout. In 2024 and 2025, the company reported increasing uptake in the United States, Europe and Japan, with quarterly product sales rising from relatively modest levels in the early launch phase to several hundred million dollars on an annualized basis, according to company filings and earnings presentations such as the full?year 2024 results published in February 2025 and subsequent quarterly updates cited by financial media at the time.

In addition to the intravenous form, Argenx SE is advancing and, in some regions, launching subcutaneous versions of Vyvgart. These are designed to offer more convenient administration and potentially expand the addressable patient pool. The company has also been conducting clinical trials to evaluate efgartigimod, the active component of Vyvgart, in other IgG?mediated indications beyond generalized myasthenia gravis. These include immune thrombocytopenia and chronic inflammatory demyelinating polyneuropathy, among others, with data readouts in 2024 and 2025 guiding regulatory strategies and label expansion efforts, as discussed in company pipeline updates and industry conference presentations.

Outside Vyvgart, Argenx SE maintains a pipeline of earlier?stage antibody candidates targeting different autoimmune pathways. These assets are at varying phases of development, from preclinical to Phase 2 or Phase 3 trials. While they do not yet contribute materially to revenue, they are important for the company’s long?term growth narrative and valuation. Management has highlighted several programs as potential follow?on pillars that could complement or diversify away from the current reliance on FcRn modulation, according to remarks made in investor presentations and conference call transcripts throughout 2024 and 2025.

Conclusion

Argenx SE has evolved into a prominent player in the autoimmune biotechnology space, with Vyvgart establishing a meaningful revenue base and supporting global expansion plans. The company continues to report growing product sales and is investing in label extensions and new indications, though it remains in a phase of high research and development spending and limited profitability. For US investors, the dual listing on Nasdaq and Euronext Brussels, combined with exposure to rare autoimmune diseases and potential long?term growth from the pipeline, makes the stock a notable name in the mid?cap biotech universe, but also one where regulatory, clinical and competitive risks need to be carefully monitored.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.